SCHEMBL4297899

SCHEMBL4297899

C=CC(=O)NNC(=N)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5470839 0.81
SCHEMBL25369963 0.81 TSHR (0.53)
SCHEMBL14520341 0.79 ALDH1A1 (0.31)
SCHEMBL1398236 0.77
SCHEMBL38662571 0.75
Bicarbonate SCHEMBL30774952 0.72 ACHE (0.40)
SCHEMBL2767461 0.72
Bicarbonate SCHEMBL19458454 0.72 ACHE (0.40)
SCHEMBL1169064 0.71
SCHEMBL909232 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119463012-A PH responsive hydrogel and preparation method and application thereof 中山大学 2025-02-18 CN disclosed
US-20090269406-A1 Therapeutic uses of biocompatible biogel compositions PANITCH ALYSSA 2009-10-29 US disclosed
CN-1249026-C N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations containing them AVENTIS PHARMA GMBH (DE) 2006-04-05 CN disclosed
US-6664393-B2 Anticoagulants AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-12-16 US disclosed
US-20030162967-A1 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-08-28 US disclosed
CN-1387508-A N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them AVENTIS PHARMA GMBH (DE) 2002-12-25 CN disclosed
US-6472562-B1 SUCH AS 4-NITRO-N-(1-CARBAMOYL-4-GUANIDINOBUTYL)-3-(2-(2,4 -DICHLOROPHENYL)ETHOXY)BENZAMIDE; ANTITHROMBOTICS; CARDIOVAS-CULAR DISORDERS LIKE THROMBOEMBOLICS OR RESTENOSES; REVERSI-BLE INHIBITORS OF BLOOD CLOTTING ENZYMES FACTOR XA, VIIA AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-10-29 US disclosed
EP-1095933-A1 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them Aventis Pharma Deutschland GmbH (DE) 2001-05-02 EP disclosed
US-5252574-A Hypotensive agents, vision disorder MERCK & CO., INC. (US) 1993-10-12 US disclosed